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COMBINING RISKS FROM SEVERAL
TUMORS USING MARKOV CHAIN
MONTE CARLO
Leonid Kopylev, John Fox, and Chao Chen
National Center for Environmental Assessment US Environmental Protection Agency

INTRODUCTION
In animal bioassays, tumors are often observed at multiple sites. Unit risk
estimates calculated on the basis of tumor incidence at only one of these sites
may underestimate the carcinogenic potential of a chemical (NRC 1994).
Furthermore the National Research Council (NRC, 1994) and Bogen (1990)
concluded that an approach based on counts of animals with one or more
tumors (counts of “tumor-bearing animals”) would tend to underestimate
overall risk when tumors occur independently across sites. On independence
of tumors, NRC (1994) stated: “… a general assumption of statistical independence of tumor-type occurrences within animals is not likely to introduce
substantial error in assessing carcinogenic potency.” Also application of a
single dose–response model to pooled tumor incidences (i.e., counts of tumorbearing animals) does not reflect possible differences in dose–response relationships across sites. Therefore the NRC (1994) and Bogen (1990) concluded
that an approach that is based on well-established principles of probability
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and statistics should be used to calculate composite risk for multiple tumors.
Bogen (1990) also recommended a re-sampling approach, as it provides a
distribution of the combined potency. Both NRC (1994) and Guidelines for
Carcinogen Risk Assessment (US EPA 2005) recommend that a statistically
appropriate upper bound on composite risk be estimated in order to gain some
understanding of the uncertainty in the composite risk across multiple tumor
sites.
This chapter presents a Markov chain Monte Carlo (MCMC) computational approach to calculating the dose associated with a specified composite
risk and a lower confidence bound on this dose, after the tumor sites of
interest (those believed to be biologically relevant) have been identified and
suitable dose–response models (all employing the same dose metric) have
been selected for each tumor site. These methods can also be used to calculate
a composite risk for a specified dose and the associated upper bound on this
risk. For uncertainty characterization, MCMC methods have the advantage of
providing information about the full distribution of risk and/or benchmark
dose. This distribution, in addition to its utility in generating a confidence
bound, provides expected values of risks that are useful for economic
analyses.
The methods presented here are specific to the multistage model with
nonnegative coefficients fitted to tumor incidence counts (i.e., summary data
rather than data on individual animals, as in the nectorine example; if data on
individual animals are available, other approaches are possible), and they
assume that tumors in an animal occur independently across sites. The nectorine example is used to illustrate proposed methodology and compare it with
the current approach.

COMBINING RISKS FOR THE MULTISTAGE MODEL
The NRC (1994) has described an approach for combining risk estimates
across tumor sites based on the multistage model: P(d, θ) = 1 − exp[−(q0 + q1d
+ q2d2 + … + qkdk)], where θ = (q0, q1, … ), qi ≥ 0, where d ≥ 0 is the
dose metric and P(d, θ) is the probability of response at dose d, with parameters θ. For the multistage model and two tumor types, A and B, assume m > k,
and
PA (d, β A ) = 1 − exp( − ( β0 A + β1 A ∗ d + … + βkA ∗ d k )) ,
PB (d, β B ) = 1 − exp( − ( β0 B + β1B ∗ d + … + β mB ∗ d m )) .
Assuming independence of tumors
PAorB (d β A, β B ) = PA (d, β A ) + PB (d, β B ) − PA (d, β A ) ∗ PB (d, β B ),
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we have,
PAorB (d, β A, β B ) = 1 − exp( − [(β0 A + β0 B ) + (β1 A + β1B ) ∗ d + … + (β kA + βkB ) ∗ d k
+ βk + 1B ∗ d k + 1 + … + β mB ∗ d m ]) .
Similarly, for more than two tumor types, the combined tumor model, Pc, is

Pc (d, θ ) = 1 − exp( − [Q0 + Q1d + Q2 d 2 + … + Qk d k ]),
where Qi = ∑qij, in which i indexes the model “stages” 1 to k and j indexes the
tumor sites, with θ = (Q0, Q1, …, Qk).
The benchmark dose method (Crump, 1984) consists of estimating a lower
confidence limit for the dose associated with a specified increase in adverse
response (i.e., increased risk) above the background level. Extra risk (ER) is
a common choice:
ER =

P (d, θ ) − P (0, θ )
.
1 − P (0, θ )

The benchmark dose (BMD) for extra risk is the solution of the above equation when the left-hand side is fixed. Statistical inference for chemical risk
assessment has mainly emphasized finding confidence limits for the BMD. For
two tumors, extra risk is given by
ERAorB (d, β A, β B ) =

PAorB (d, β A, β B ) − PAorB (0, β A, β B )
.
1 − PAorB (0, β A, β B )

After simple algebra,
ERAorB (d, β A, β B ) = 1 − exp( − [(β1 A + β1B ) ∗ d + … + (βkA + βkB ) ∗ d k + βk + 1B ∗ d k + 1
+ … + β mB ∗ d m ]) .
BMD for combined risk BMRAorB is (after re-arranging and taking logarithms
of both sides) the solution to the polynomial
−log (1 − BMRAorB ) = (β1 A + β1B ) ∗ d + … + (βkA + βkB ) ∗ d k
+ βk + 1B ∗ d k + 1 + … + β mB ∗ d m .

A similar polynomial equation applies when more than two tumors are
observed in a bioassay.

200

COMBINING RISKS FROM SEVERAL TUMORS USING MCMC

BAYESIAN APPROACH
A Bayesian approach for calculating a confidence bound on the BMD for
composite risk can be implemented using WinBUGS (Spiegelhalter et al.,
2003). This is a freely available software package that can be used to apply
MCMC methods (e.g., Smith and Gelfand, 1992; Casella and George, 1992;
Chib and Greenberg, 1995; Brooks, 1998; Gilks et al., 1998; Gelman et al.,
2004). Gelfand et al. (1992) discusses MCMC methods involving constraints,
as in the case of applying the multistage dose–response model to the nectorine
data, where maximum likelihood estimates (MLE) for background coefficients
for both tumors are on the boundary.
The use of MCMC methods (via WinBUGS) to derive a posterior distribution of BMDs for a single multistage model has been recently described
by Kopylev et al. (2007). This methodology can be straightforwardly generalized to derive a posterior distribution of BMDs for combined tumor risk
across sites, using the approach for composite risk described in the previous
section.
The mode and 5th percentile of the resulting posterior distribution of the
dose for a fixed extra risk provide estimates of the BMD and the BMDL
(“lower bound”) for composite tumor risk. Similarly, the mean and 95th percentile of the posterior distribution of the composite extra risk provide estimates of the expected extra risk and the upper bound on the extra risk.

EXAMPLE
The data for the nectorine bioassay are given in Table 5.1. Two tumor types
were observed and no information beyond summary data is available.
A linear multistage model fits better—based on lowest values of the deviance information criterion (DIC) reported by WinBUGS—than a quadratic
or cubic model for both adenoma and neuroblastoma tumors. Similarly a
linear model is preferable for both tumors, based on minimizing AIC—based
on BMDS (US EPA 2006) computations. The WinBugs results are obtained
based on convergence of 3 chains with different initial values, and 50,000 burnin (i.e., the first 50,000 samples discarded) from 50,000 simulations each, using
WinBUGS 1.4.1. The posterior distribution is obtained from the combined

TABLE 5.1

Nectorine bioassay data
Concentration (ppm)

Tumor Type
Respiratory epithelial adenoma
Olfactory epithelial neoblastoma

0

10

30

60

0/49
0/49

6/49
0/49

8/48
4/48

15/48
3/48
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150,000 samples from the three chains and thinned by retaining every 10th
sample to reduce autocorrelation, resulting in 15,000 samples. A prior that is
a mixture of a diffuse continuous distribution on a positive real line and a
point mass at 0 was used for multistage parameters. In WinBUGS the prior
was constructed by truncating a high-variance Gaussian prior distribution at
−1 and using the “step” function to collect mass from the interval on the negative real line at 0 as a point mass. In a limited Monte Carlo simulation of the
frequentist properties of the posterior, this was a reasonable choice for a range
of scenarios we investigated.
The posterior distribution of the extra risk at dose 11 ppm and BMD10 is
shown on Figures 5.1 and 5.2 (11 ppm is chosen because it is close to the combined BMD10). The posterior distribution of the linear coefficient for the
neoblastoma tumor is strongly bimodal with 40% of its mass at 0 and the rest
of the mass continuously distributed. In a linear model, lack of the linear
term implies no extra risk; that is, risk is the same at every dose. Since the
extra risk for a linear model is a 1 : 1 function of the linear parameter, there is
also bimodality of extra risk for neoblastoma in Figure 5.1. As the BMD in a
linear model is inversely proportional to the linear term, for that 40% of
neuroblastoma simulations in which the estimated linear term was zero, the
BMD (Figure 5.2) could not be determined (mathematically it is infinite). In
contrast, the linear parameter for the adenoma model has a unimodal posterior bounded away from zero (and so the extra risk distribution for adenoma
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Distribution of extra risk for individual and combined tumors
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Figure 5.1 Distribution of the extra risk at dose 11 ppm for individual and combined
tumors for the nectorine example. Note that 40% of the distribution for neuroblastoma
extra risk is at 0, since the posterior of the linear parameter for this model has 40% of
its mass at 0.
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Figure 5.2 Distribution of the logarithm of BMD10 for individual and combined
tumors in the nectorine example. Letters “B” on the x-axis indicate BMD10s for
adenoma and combined tumors. For 40% of neuroblastoma simulations (see Figure 5.1
caption), BMD cannot be determined (is infinite); thus the integral under the distribution for neuroblastoma is 0.6.

TABLE 5.2

Statistics for individual and combined BMD10 for the nectorine example
WinBUGS

Approach
Adenoma
Neuroblastoma
Combined

BMDS

5th
Percentile
(BMDL)

Posterior
Mode
(BMD)

95th
Percentile
BMDU

5th
Percentile
(BMDL)

MLE
(BMD)

95th
Percentile
BMDU

11.06
40.63
8.69

14.20
&
11.24

20.63
&
20.63

11.32
39.91
9.58*

15.17
70.11
12.47

22.79
153.60
*

Note: & indicates BMD and BMDU for neuroblastoma could not be determined for 40% of simulations;
*indicates lower confidence bound on BMD is obtained with a BMDS module that is still under development. This software does not calculate BMDU.

(Figure 5.1) is also bounded away from 0); consequently the distribution of
BMD and extra risk for combined tumors is well defined.
Tables 5.2 and 5.3 show individual and combined BMDs and extra risks
calculated by two approaches: WinBUGS and BMDS (US EPA 2006). Lower
confidence bound on combined BMD (Table 5.2) is obtained by an experimental module of BMDS, which is still undergoing testing. That module uses a
profile likelihood approach similar to the current approach for an individual
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TABLE 5.3
example

Statistics for individual and combined extra risks for the nectorine
WinBUGS

Approach
Adenoma
Neuroblastoma
Combined

BMDS

5th
Percentile

Mean

95th
Percentile

5th
Percentile

MLE

95th
Percentile

0.055
0
0.059

0.076
0.011
0.086

0.099
0.028
0.135

0.048
0.007
*

0.072
0.016
0.088

0.097
0.028
0.115*

Note: For *, see caption for Table 5.2.

tumor in BMDS. Also note that for the extra risk WinBUGS provides estimates
of average extra risk, whereas BMDS provides estimates of MLE extra risk.
Interestingly, while BMDLs calculated by two methods are quite close for
individual tumors, there is a difference in combined BMDL (Table 5.2) and
upper bound on extra risk (Table 5.3).
It is clear from the figures that risk of adenoma dominates the risk of neuroblastoma. However, even for this example, with markedly unequal risks from
the tumors, the extra risk can be substantially greater when risks are combined.
For example, Table 5.3 shows that the 95th percentile risk at 11 ppm is about
35% greater for combined risk than for adenoma alone (WinBUGS computation). The difference for average risk is less pronounced (13% larger) but still
nontrivial.

DISCUSSION
In this chapter, an application of Bayesian methods for calculating probability
distributions for composite cancer risk estimates is proposed. Advantages of
the proposed approach are that the concept can easily be extended to a more
general case, such as a Bayesian hierarchical model with covariates, and computations are easy to implement.
As NRC (1994) stated, ignoring issues about combining tumors could lead
to underestimation of risk. In this example with an order of magnitude difference between individual tumors, the underestimation was moderate, compared
to other uncertainties inherent to extrapolating risk from animals to humans.
It is easy to see that in some situations (e.g., more than two tumors or tumors
of similar potency), ignoring additional tumors could lead to a serious underestimation of risk from a toxic substance.
It is very important to choose an appropriate prior when parameter estimates are either on the boundary of the parameter space or are near the
boundary for a finite sample. We chose a prior that is a mixture of a diffuse
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continuous prior over the nonnegative real line and a small point mass at 0.
In limited Monte Carlo simulations such mixture priors performed reasonably
well in a frequentist sense. Using a continuous prior over the nonnegative real
line could lead to undesirable frequentist properties of the posterior when
model parameters are at or near the boundaries of parameter space (zero for
parameters of the multistage model). However, further research is needed to
determine the optimal way of allocating prior density to the point mass at 0
and the continuous nonnegative part.
The approach presented in this chapter provides statistical uncertainty in
risk estimates conditional on the data set and multistage models of specified
order. The approach can be straightforwardly extended to models other than
the multistage model; Bayesian model selection could also be used. However,
the uncertainty discussed in this article is only for a particular dose–response
model and does not address uncertainty associated with the selection of a
particular model, or a set of models.
The approach assumes independence of tumors given dose. Independence
may not be true for some types of tumors. Possible next steps include investigation of consequences of violation of independence assumption, and ways to
evaluate and incorporate dependence in the methodology.
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